Phoenix, Arizona, United States, October 13, 2026
GT Medical Technologies, Inc., a medical device company specializing in surgically targeted radiation therapy for brain tumors, has announced a new designation under its GammaTile® Center of Excellence Program. The program recognizes healthcare institutions that demonstrate a commitment to advancing the use of GammaTile, an implantable radiation therapy device designed for patients undergoing brain tumor surgery. The designation highlights the participating center’s focus on specialized neurosurgical care, clinical expertise and the integration of targeted radiation treatment into multidisciplinary brain tumor management. GammaTile combines collagen-based tiles with embedded cesium-131 radioactive sources, allowing radiation to be delivered directly to the surgical cavity following tumor removal. This approach is intended to provide localized radiation while limiting exposure to surrounding healthy brain tissue. The Center of Excellence initiative supports clinical education, professional collaboration and the dissemination of experience with this specialized treatment option. The designation is a recognition of clinical and institutional commitment, rather than a new FDA approval or proof of superior treatment outcomes. GT Medical continues to expand awareness of GammaTile as an option for selected patients with certain brain tumors.
GammaTile Provides Targeted Radiation After Brain Surgery
GammaTile is an FDA-cleared, surgically targeted radiation therapy that combines a bioresorbable collagen tile with embedded cesium-131 brachytherapy sources. It is designed to be placed into the cavity created when a brain tumor is surgically removed. The radioactive sources deliver radiation directly to the surrounding tissue where residual tumor cells may remain, with the goal of reducing the likelihood of local recurrence. Unlike external-beam radiation, which delivers radiation from outside the body, GammaTile is implanted during surgery and begins delivering radiation immediately after placement. The cesium-131 sources release radiation over a relatively short period, providing a localized treatment approach that is integrated into the surgical procedure. GammaTile is used in selected patients with certain primary and recurrent brain tumors, subject to its authorized indications and clinical judgment. Treatment decisions require consideration of tumor type, location, previous therapies, overall health and the potential benefits and risks of surgery and radiation. GammaTile does not eliminate the possibility of tumor recurrence, and outcomes vary according to the patient’s condition and disease characteristics. The technology is intended to complement established brain tumor treatment approaches rather than replace every other form of cancer care.
Center of Excellence Program Promotes Clinical Expertise
GT Medical Technologies established its GammaTile Center of Excellence Program to recognize institutions that demonstrate experience and commitment to the technology and its use in brain tumor treatment. The program is intended to support education, collaboration and the exchange of clinical experience among neurosurgeons, radiation oncologists and other specialists involved in brain tumor care. A multidisciplinary approach is particularly important in neuro-oncology because treatment planning may involve neurosurgical removal, radiation therapy, medical oncology, pathology and long-term monitoring. Institutions participating in specialized programs can help share practical insights on patient selection, surgical workflows and coordination of postoperative care. The new designation expands the network of centers recognized by GT Medical for their involvement with GammaTile. However, a Center of Excellence designation should not be interpreted as independent certification of superior patient outcomes unless supported by specific, independently validated criteria and outcome data. The announcement reflects the company’s efforts to encourage appropriate use and awareness of the technology within specialized clinical settings. Continued evidence generation and professional education remain important as clinicians assess the role of surgically targeted radiation in different brain tumor populations.
Advertisement
Targeted Radiation Addresses Unmet Needs in Neuro-Oncology
Brain tumors can be difficult to treat because of their location, proximity to critical neurological structures and the potential for residual cancer cells following surgery. Even after a tumor is removed, microscopic disease may remain near the surgical cavity, creating a risk of local recurrence. Radiation therapy can help address residual disease, but treatment planning must balance tumor control with the need to protect healthy brain tissue. GammaTile offers a localized brachytherapy approach that allows radiation to be delivered at the surgical site during the same procedure used to remove the tumor. Its design may reduce the need for a separate radiation-planning and treatment phase in appropriate patients, although the overall treatment pathway depends on individual clinical circumstances. GT Medical Technologies focuses on developing and commercializing this approach for selected brain tumor indications. As clinical experience grows, ongoing research will be important for clarifying which patients are most likely to benefit, how GammaTile compares with other treatment strategies and what outcomes can be expected over longer follow-up periods. The Center of Excellence Program is intended to support a community of institutions familiar with the technology and its role in multidisciplinary brain tumor management.
The new designation represents another development in GT Medical Technologies’ efforts to expand awareness of GammaTile surgically targeted radiation therapy. By recognizing participating institutions and encouraging collaboration among specialists, the program aims to support informed clinical use of an implantable treatment designed for selected patients undergoing brain tumor surgery. Continued clinical evidence, professional training and appropriate patient selection will remain essential to determining the technology’s role in neuro-oncology.
Source: GT Medical Technologies press release
